Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Softer catheters could save millions of failed IVs

NCT ID NCT06927141

Knowledge-focused Sponsor: Griffith University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a softer, more flexible catheter material reduces irritation and failure of intravenous lines. Twenty-seven healthy adults each received two catheters (one standard, one more flexible) in opposite arms for up to 72 hours. Researchers measured catheter angle, fluid leakage, clotting, and how long each catheter lasted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Peripheral intravenous catheter (cannula) with more flexible tip material
What this could lead to
If successful, this could lead to longer-lasting catheters that reduce the need for reinsertion and lower complication rates.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. Results may not apply to real-world hospital settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

May 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult aged 18-75 years. * Not pregnant at time of recruitment and within 48 hrs of Day 1 procedures (self-reported) * Normal haematology results as per reference range determined by the laboratory. * Normal coagulation results as per reference range determined by the laboratory. * Target cephalic veins readily cannulatable (i.e., \> 2 mm) * Able and willing to provide verbal and written consent * Must be an Australian citizen with current Medicare card Exclusion Criteria: * History of pro coagulative state / condition (e.g., previous deep vein thrombosis) * Currently on any anti-coagulant or platelet inhibitor medication. Use of NSAIDs and aspirin will be documented however are not exclusionary. * Haemophilia or any current or history of bleeding disorder or tendency * Presence or report of current blood borne disease/infection (e.g., hepatitis, HIV, leukemia, lymphoma) * History of difficult vascular access * Allergy or sensitivity to chlorhexidine gluconate, isopropyl alcohol, latex, or skin adhesives * BMI \< 18.5 kg/m2 or ≥ 35 kg/m2 * Positive results for the urine drug screen at screening or check-in (including opiates, methadone, cocaine, amphetamines) * History or presence of alcoholism (self-reported) or drug abuse within the past 2 years * A current or previous medical, physical, mental / cognitive disorder or anatomical conditions that, in the opinion of the chief or sub-investigator, would place the patient at risk, would make them unable to perform study procedures or has the potential to confound interpretation of the study results. (e.g., musculo-skeletal injury, chronic back pain) * Employed by Terumo, Becton Dickinson, Teleflex Medical, ICUMedical or BBraun (conflict of interest)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Edema thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy Intravenous catheterization Oedema Thrombosis

Contacts and locations

Locations

  • Griffith University

    Southport, Queensland, 4215, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.